Bio-Rad Laboratories Inc., a leader in the Bio-Tech market, is getting increased attention from investors. The
Manufacturers Life Insurance Company and other firms like
Charles Schwab Investment Management Inc. and
Natixis Advisors have adjusted their stock holdings in Bio-Rad lately. On the other hand, the company's
shares have experienced some fluctuations witnessing a substantial
relative price strength rise, but also facing a depreciation, including a 5.5% drop after the last earnings report. Recent
analyses provide differing views, citing the company as potentially
undervalued, but others argue it's overvalued based on
fundamental and DCF analyses. Despite some setbacks, Bio-Rad hit a
52-week high of $365.65 amid robust growth, and posted
strong sales in diagnostics unit.
Various key investments were made by
DRW Securities, Entropy Technologies, and Rovin Capital UT ADV, boosting the company’s position.
Zacks Research predictions for the 2024 fiscal year and analysts eyeing intrinsic value inform investors about Bio-Rad's potential. However, the company’s stock has taken a hit with
shareholders facing significant
losses in the past three years and the last week.
Bio-Rad Laboratories Stocks News Analytics from Tue, 31 Aug 2021 21:03:23 GMT to Sat, 30 Nov 2024 17:40:00 GMT -
Rating 2
- Innovation -1
- Information 7
- Rumor -3
